Literature DB >> 24447807

Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists.

D Dubois-Laforgue1, D Boutboul2, D J Lévy2, D Joly3, J Timsit2.   

Abstract

We report two patients with diabetes in whom acute renal failure requiring hemodialysis occurred while on treatment with glucagon-like peptide-1 receptor agonists. We discuss the mechanisms of this complication and the potential for its prevention.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Acute interstitial nephritis; Acute renal failure; Exenatide; Glucagon-like peptide-1 receptor agonists; Liraglutide; Type 2 diabetes mellitus

Mesh：

Substances：

Year:  2013        PMID： 24447807     DOI： 10.1016/j.diabres.2013.11.014

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  10 in total

Review 1.  Adverse Effects of GLP-1 Receptor Agonists.

Authors:  Theodosios D Filippatos; Thalia V Panagiotopoulou; Moses S Elisaf
Journal:  Rev Diabet Stud       Date:  2015-02-10

Review 2.  Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making.

Authors:  Gerhard H Scholz; Holger Fleischmann
Journal:  Ther Adv Endocrinol Metab       Date:  2014-10       Impact factor: 3.565

Review 3.  Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

Review 4.  Post-transplant diabetes mellitus in patients with solid organ transplants.

Authors:  Trond Jenssen; Anders Hartmann
Journal:  Nat Rev Endocrinol       Date:  2019-03       Impact factor: 43.330

5.  Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury.

Authors:  Min Zhao; Shusen Sun; Zhenguang Huang; Tiansheng Wang; Huilin Tang
Journal:  Clin J Am Soc Nephrol       Date:  2020-12-29       Impact factor: 8.237

Review 6.  Interactions between kidney disease and diabetes: dangerous liaisons.

Authors:  Roberto Pecoits-Filho; Hugo Abensur; Carolina C R Betônico; Alisson Diego Machado; Erika B Parente; Márcia Queiroz; João Eduardo Nunes Salles; Silvia Titan; Sergio Vencio
Journal:  Diabetol Metab Syndr       Date:  2016-07-28       Impact factor: 3.320

7.  Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study.

Authors:  Jianwen Wang; Jie Huang; Wei Li; Shiqi Tang; Jian Sun; Xianming Zhang; Jun Liu; Bin Yi; Jishi Liu; Xingfei Zhang; Qian Yang; Xiaoyan Yang; Shuang Yang; Guoping Yang; Hao Zhang
Journal:  Br J Clin Pharmacol       Date:  2019-12-08       Impact factor: 4.335

Review 8.  Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases.

Authors:  Wei Peng; Rui Zhou; Ze-Fang Sun; Jia-Wei Long; Yong-Qiang Gong
Journal:  Aging Dis       Date:  2022-04-01       Impact factor: 6.745

9.  Exendin-4 Exacerbates Burn-Induced Morbidity in Mice by Activation of the Sympathetic Nervous System.

Authors:  Xiao-Jing Ji; Ji-Wei Hao; Guang-Lei Li; Ning Dong; Xin-Qi Wang; Min Zhou; Qing-Hong Zhang; Yong-Ming Yao
Journal:  Mediators Inflamm       Date:  2019-01-17       Impact factor: 4.711

Review 10.  The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes.

Authors:  Win L Yin; Steve C Bain; Thinzar Min
Journal:  Diabetes Ther       Date:  2020-03-17       Impact factor: 2.945
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.